Michael Matson, an analyst from Needham, reiterated the Buy rating on Stryker. The associated price target remains the same with $448.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Michael Matson has given his Buy rating due to a combination of factors that highlight Stryker’s strong position in the sector. During the investor day on November 13, 2025, Stryker’s management outlined their strategic plans, operational updates, and financial targets for the coming years. These include revenue growth, operating margin improvements, and EPS growth projections for 2026 to 2028 that align with market expectations.
Despite a predicted slowdown in operating margin improvement, which is expected to average around 50 basis points per year from 2026 to 2028, this has been anticipated by the market. Stryker’s focus on mergers and acquisitions, along with its strategy of launching new products and gaining market share, supports the expectation of continued sector-leading growth. These factors contribute to Matson’s confidence in maintaining a Buy rating for Stryker.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $435.00 price target.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year.